Skip to main content
OpenTrials
Completed

NCT Number: NCT02164500

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recurrent Classical Hodgkin Lymphoma

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

1st Dept. of Medicine, Cologne University Hospital

Cologne, 50924, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • relapsed or refractory HL
  • ECOG <= 2,
  • no major organ dysfunction
  • written informed consent

Exclusion criteria

  • history of another primary malignancy ≤ 2 years
  • female patients who are pregnant or breast feeding
  • patients with a known history of HIV seropositivity
  • chronic active hepatitis

Treatment and study plan

Ruxolitinib

Drug

Primary outcomes

  1. overall response rate

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Registry information

Official study title

A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Acronym: JeRiCHO

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jun 16, 2014
Registry last updated
Apr 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.